What is The Most Popular Next-Generation Sequencer and The Most Common Applications For It? New Report Reveals Survey Results

ROCKVILLE, Md., Feb. 15, 2018 /PRNewswire/ -- Kalorama Information's recent survey of Next Generation labs find thats the MiSeq is the most commonly owned brand, and that resequencing and RNA sequencing are among the most common.  Kalorama conducted the survey of NGS-capable labs around the world, with 83% of the respondents in the U.S. and Europe.   Kalorama Information's report Next Generation Sequencing Trends is available at: https://www.kaloramainformation.com/Generation-Sequencing-Trends-Kalorama-Survey-Laboratories-11293078/.

When asked about sequencer model ownership, the following were the results of Kalorama's survey:

• MiSeq - 22.6%
  
  
• Nextseq (all) - 12.0%
  
  
• Hiseq 2500 - 11.7%
  
  
• Hiseq 4000 - 6.6%
  
  
• Ion Proton - 6.2%
  
  
• ABI 3730xl - 5.5%
  
  
• ABI 3730 - 5.1%
  
  
• Ion Torrent PGM - 3.6%
  
  
• Pac Bio Sequel - 3.6%

When asked about applications that were expected to increase in the future, NGS-owning laboratories though the following:

• Resequencing/ amplicon - 50.9%
  
  
• RNA seq, transcriptomics, gene expr. - 41.5%
  
  
• Metagenomics - 17.0%
  
  
• De novo sequencing & whole genome - 17.0%
  
  
• Exome - 15.1%
  
  
• Methylation, other epigenetics - 7.5%

Kalorama's study includes far more research including which sequencers tended to be present in labs that owned other sequencers, which applications are currently being performed most (by model of sequencer), key bottlenecks and future purchase brands.

The study focuses on a survey of 78 laboratories which was carried out from August to October of 2017.  The survey effort targeted labs likely to be doing, or likely to be planning, applications of sequencing in either diagnostic or clinical research settings.  Due to the increasing importance of next-generation systems in the market, the scope leans towards these types of sequencers.    The mix of labs reached in the surveys provides both a range of industry segments as well as groups of labs with both types of systems.

Labs were mostly contacted by phone and asked to participate in a phone interview/ survey for around 10 to 15 minutes.  A small fraction of the labs completed the survey on a website set up with the questions.  Some potential participants were offered the incentive of being included in a drawing for a gift card, but many turned that down.  The survey included the following, some open-ended and some multiple-choice type questions, in abbreviated form:

• Please describe the lab's industry and function?
  
  
• How many sequencers does the laboratory have, and which models?
  
  
• For your most recent sequencers, please describe: the model, what applications are run typically (by percentage), how often or how many samples (runs, samples, slides, flow cells, plates, multiplexed or not).
  
  
• Which applications are expected to increase most?
  
  
• Does the lab outsource any sequencing? For what reason(s)?
  
  
• How does the lab/ organization address regulated patient samples?
  
  
• Does the lab have accreditation for regulated patient samples?
  
  
• Which sequencers are used for regulated and non-regulated patient samples?
  
  
• In what disease areas does the lab sequence regulated/ non-regulated patient/ human samples?  What disease areas are expected to grow the most from 2017-2018?
  
  
• What percentage of samples sequenced are patient samples subject to regulation, patient/ human samples not subject to regulation, and non-patient/ non-human samples not subject to regulation?  How is this expected to change from 2017-2018
  
  
• How much is the volume of NGS and capillary sequencing expected to change overall from 2017 to 2018?
  
  
• What sequencer features, or steps in the sequencing process would you most like to be changed/ improved?
  
  
• What is the main bottleneck in your sequencing process (i.e., at what step do things back up)?
  
  
• How challenging are data analysis and data management?
  
  
• Which systems would the lab most likely consider for future purchases?
  
  
• What is the likely time frame for future sequencer purchases?
  
  
• Which systems are likely to be used in the future for regulated patient samples (and are not being used currently for that)?
  
  
• What barriers or other issues would hinder the growth of sequencing, particularly NGS, in clinical areas?

Kalorama Information's report, Next Generation Sequencing Trends can be found at: https://www.kaloramainformation.com/Generation-Sequencing-Trends-Kalorama-Survey-Laboratories-11293078/

About Kalorama Information

Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. Reports can be purchased through Kalorama's website and are also available on www.marketresearch.com and www.profound.com.

We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog on our company website.  

Press Contact:                                                        
Bruce Carlson
212 807 2262   
[email protected]

SOURCE Kalorama Information

Related Links

https://www.kaloramainformation.com